Skip to main content
Clinical Trials/ACTRN12606000010594
ACTRN12606000010594
Withdrawn
Phase 2

Phase II Study to Determine Predictive Markers of Response to MDX-010 (BMS-734016) in Patients with Unresectable Stage III or IV Malignant Melanoma

Bristol-Myers Squibb Pty Ltd.0 sites80 target enrollmentJanuary 4, 2006

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
nresectable Stage III or IV Malignant Melanoma
Sponsor
Bristol-Myers Squibb Pty Ltd.
Enrollment
80
Status
Withdrawn
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 4, 2006
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Bristol-Myers Squibb Pty Ltd.

Eligibility Criteria

Inclusion Criteria

  • Histologic or cytologic diagnosis of unresectable Stage III or IV malignant melanoma (excluding ocular melanoma). A pre\- and post\-treatment fresh core or excision tumour biopsy must be provided.

Exclusion Criteria

  • No exclusion criteria

Outcomes

Primary Outcomes

Not specified

Similar Trials